Mar 1, 2023 · -- GC Biopharma signed a deal with US-based drug developer Catalyst Biosciences to take over its orphan hematology disorder treatment candidates including Marzeptacog alfa, The Korea Herald reported.

Mar 1, 2023 · -- GC Biopharma signed a deal with US-based drug developer Catalyst Biosciences to take over its orphan hematology disorder treatment candidates including Marzeptacog alfa, The Korea Herald reported.

. Feb 28, 2023 · Catalyst Biosciences ( CBIO) stock is rising an asset sale agreement.

The company recently reported positive results from its.

That’s because.

(CBIO) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). Over the past three months, the Zacks Consensus Estimate for CBIO's full-year earnings has moved 23. The buyer of these programs is GC Biopharma.

The company is selling three programs connected to orphan hematology disorders.

. sells Wakix for narcolepsy patients. CBIO's rank also includes a short-term.

. Mar 17, 2023 · LifeSci Capital analyst Sam Slutsky maintained a Buy rating on Catalyst Biosciences (CBIO - Research Report) today and set a price target of $0.

7% and a 45.

.

(CBIO) NasdaqCM - NasdaqCM Real Time Price. 1 day ago · In a report released today, Sam Slutsky from LifeSci Capital maintained a Buy rating on Cogent Biosciences (COGT – Research Report), with a price target of $26.

(NASDAQ: CBIO) stock closed at 0. .

.
An upward.
.

.

76M.

The average rating score is and is based on 1 buy ratings, 0 hold ratings, and 0 sell ratings. The Last 12 Months Of Insider Transactions At Catalyst Biosciences. May 23, 2022 · Catalyst Biosciences (NASDAQ: CBIO) stock is jumping on the sale of its protease medicines portfolio.

. . (CBIO) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). Jan 12, 2022 12:00PM EST. Jan 12, 2022 · Catalyst Biosciences, Inc. .

.

-- GC Biopharma signed a deal with US-based drug developer Catalyst Biosciences to take over its orphan hematology disorder treatment candidates including Marzeptacog alfa, The Korea Herald reported. .

18% PDF.

BUY: Number of Analysts: 9: Last Close Price: 128 000,00 KRW: Average target price: 159 888,89 KRW:.

.

.

.